Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
140 Pages - GMD12036
$2,000.00

Summary

Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Cutaneous T-Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cutaneous T-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cutaneous T-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cutaneous T-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cutaneous T-Cell Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Cutaneous T-Cell Lymphoma - Overview 10
Pipeline Products for Cutaneous T-Cell Lymphoma - Comparative Analysis 11
Cutaneous T-Cell Lymphoma - Therapeutics under Development by Companies 12
Cutaneous T-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 15
Cutaneous T-Cell Lymphoma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Cutaneous T-Cell Lymphoma - Products under Development by Companies 20
Cutaneous T-Cell Lymphoma - Products under Investigation by Universities/Institutes 21
Cutaneous T-Cell Lymphoma - Companies Involved in Therapeutics Development 22
Johnson & Johnson 22
Kyowa Hakko Kirin Co., Ltd. 23
Seattle Genetics, Inc. 24
Novartis AG 25
Eisai Co., Ltd. 26
Galderma S.A. 27
Onyx Pharmaceuticals, Inc. 28
Mundipharma International Limited 29
Innate Pharma SA 30
Chipscreen Biosciences Ltd 31
Therametrics holding AG 32
TetraLogic Pharmaceuticals 33
Hy BioPharma Inc. 34
OncoSec Medical Inc. 35
Cutaneous T-Cell Lymphoma - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 40
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
mogamulizumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
brentuximab vedotin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
HBP-347 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
panobinostat - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
HBI-8000 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
everolimus - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
forodesine hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
quisinostat - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DNA IL-12 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
OMSI-120 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
A-dmDT390-bisFv - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
carfilzomib - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SHP-141 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CD-5789 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Genetically Modified T Cells-1138 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
IPH-4101 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
thymopentin - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Angeloxin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Immunotoxins - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Tumor Loaded Dendritic Cell Immunotherapy - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
bexarotene - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Cutaneous T-Cell Lymphoma - Recent Pipeline Updates 92
Cutaneous T-Cell Lymphoma - Dormant Projects 129
Cutaneous T-Cell Lymphoma - Discontinued Products 130
Cutaneous T-Cell Lymphoma - Product Development Milestones 131
Featured News & Press Releases 131
Apr 07, 2014: OncoSec Medical To Relaunch Phase II Cutaneous T-Cell Lymphoma Study at Key Centers of Excellence 131
Jan 15, 2014: Addition of Japanese Sites for Pivotal Phase 3 Trial of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma 132
Oct 08, 2013: OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study 132
Aug 26, 2013: Ceptaris Receives FDA Approval for VALCHLOR Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy 133
Aug 08, 2013: FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma 134
Jul 24, 2013: Inovio Pharmaceuticals' Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence 134
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 136
Apr 12, 2013: Elorac's Naloxone Topical Lotion Receives FDA Fast Track Designation For Relief Of Pruritus In Patients With Cutaneous T-cell Lymphoma 136
Mar 04, 2013: Shape Pharma Provides Update On SHP-141 Topical HDAC Inhibitor Clinical Development For Cutaneous T Cell Lymphoma 137
Feb 27, 2013: Ceptaris Resubmits New Drug Application To FDA For Gel Formulation Of Mechlorethamine Hydrochloride 137
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 140
Disclaimer 140

List of Tables
Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2014 10
Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Cutaneous T-Cell Lymphoma - Pipeline by Johnson & Johnson, H1 2014 22
Cutaneous T-Cell Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 23
Cutaneous T-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014 24
Cutaneous T-Cell Lymphoma - Pipeline by Novartis AG, H1 2014 25
Cutaneous T-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2014 26
Cutaneous T-Cell Lymphoma - Pipeline by Galderma S.A., H1 2014 27
Cutaneous T-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 28
Cutaneous T-Cell Lymphoma - Pipeline by Mundipharma International Limited, H1 2014 29
Cutaneous T-Cell Lymphoma - Pipeline by Innate Pharma SA, H1 2014 30
Cutaneous T-Cell Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2014 31
Cutaneous T-Cell Lymphoma - Pipeline by Therametrics holding AG, H1 2014 32
Cutaneous T-Cell Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H1 2014 33
Cutaneous T-Cell Lymphoma - Pipeline by Hy BioPharma Inc., H1 2014 34
Cutaneous T-Cell Lymphoma - Pipeline by OncoSec Medical Inc., H1 2014 35
Assessment by Monotherapy Products, H1 2014 36
Number of Products by Stage and Target, H1 2014 39
Number of Products by Stage and Mechanism of Action, H1 2014 42
Number of Products by Stage and Route of Administration, H1 2014 44
Number of Products by Stage and Molecule Type, H1 2014 46
Cutaneous T-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 92
Cutaneous T-Cell Lymphoma - Dormant Projects, H1 2014 129
Cutaneous T-Cell Lymphoma - Discontinued Products, H1 2014 130

List of Figures
Number of Products under Development for Cutaneous T-Cell Lymphoma, H1 2014 10
Number of Products under Development for Cutaneous T-Cell Lymphoma - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 36
Number of Products by Top 10 Target, H1 2014 37
Number of Products by Stage and Top 10 Target, H1 2014 38
Number of Products by Top 10 Mechanism of Action, H1 2014 40
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 41
Number of Products by Top 10 Route of Administration, H1 2014 43
Number of Products by Stage and Top 10 Route of Administration, H1 2014 44
Number of Products by Top 10 Molecule Type, H1 2014 45
Number of Products by Stage and Top 10 Molecule Type, H1 2014 46

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax